儿童SARS-CoV-2相关凝血病与血栓预防:单中心观察性研究
结果显示D-二聚体不能区分COVID-19严重程度,但COVID-19与MIS-C队列间差异显著;6例有多种血栓风险因素者启动药物预防,无死亡或血栓/出血并发症。
要点
- D-二聚体不能区分儿童COVID-19严重程度,但COVID-19与MIS-C间差异显著。
- MIS-C病例显示炎症驱动的促凝血状态实验室迹象。
- 不推荐对所有住院SARS-CoV-2相关表现儿童普遍抗凝预防。
核心结论
- 儿童COVID-19患者凝血和炎症参数轻度改变,MIS-C病例显示炎症驱动的促凝血状态。
- 对所有住院SARS-CoV-2相关表现儿童普遍抗凝预防不必要,但可对具有其他血栓风险因素的患者在多模式治疗中提供预防。
研究设计与样本
- 在中重度至危重患者和MIS-C病例中,多时间点检测凝血和炎症标志物并比较中位数结果。
主要发现
- 诊断时D-二聚体值不能区分COVID-19不同严重程度,但在COVID-19与MIS-C队列间差异显著。
- 两个队列中,临床恶化时D-二聚体和C反应蛋白水平升高,但纤维蛋白原或血小板值未降低,所有参数在疾病缓解后恢复正常。
- 6例患者有多种血栓风险因素并启动药物血栓预防,无死亡或血栓或出血并发症发生。
关键数值与推荐
- D-二聚体值在COVID-19与MIS-C队列间差异显著。
- 6例患者有多种血栓风险因素并启动药物血栓预防。
- 无死亡或血栓或出血并发症发生。
临床怎么用
- 对住院SARS-CoV-2相关表现儿童,不推荐普遍抗凝预防。
- 可对具有其他血栓风险因素的患者在多模式治疗中考虑药物血栓预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple investigators have described an increased incidence of thromboembolic events in SARS-CoV-2-infected individuals. Data concerning hemostatic complications in children hospitalized for COVID-19/multisystem inflammatory syndrome in children (MIS-C) are scant. OBJECTIVES: To share our experience in managing SARS-CoV-2-associated pro-coagulant state in hospitalized children. METHODS: D-dimer values were recorded at diagnosis in children hospitalized for SARS-CoV-2-related manifestations. In moderately to critically ill patients and MIS-C cases, coagulation and inflammatory markers were checked at multiple time points and median results were compared. Pro-thrombotic risk factors were appraised for each child and thromboprophylaxis was started in selected cases. RESULTS: Thirty-five patients were prospectively enrolled. D-dimer values did not discriminate COVID-19 of differing severity, whereas were markedly different between the COVID-19 and the MIS-C cohorts. In both cohorts, D-dimer and C-reactive protein levels increased upon clinical worsening but were not accompanied by decreased fibrinogen or platelet values, with all parameters returning to normal upon disease resolution. Six patients had multiple thrombotic risk factors and were started on pharmacological thromboprophylaxis. No deaths or thrombotic or bleeding complications occurred. CONCLUSIONS: COVID-19 pediatric patients show mildly altered coagulation and inflammatory parameters; on the other hand, MIS-C cases showed laboratory signs of an inflammatory driven pro-coagulant status. Universal anticoagulant prophylaxis in hospitalized children with SARS-CoV-2-related manifestations is not warranted, but may be offered to patients with other pro-thrombotic risk factors in the context of a multi-modal therapeutic approach.
引用
- Del Borrello G, Giraudo I, Bondone C, et al. SARS-COV-2-associated coagulopathy and thromboembolism prophylaxis in children: A single-center observational study. J Thromb Haemost. 2020. PMID: 33305475. doi:10.1111/jth.15216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。